Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 2
1954 3
1955 2
1956 1
1959 1
1960 1
1964 1
1970 1
1976 5
1977 3
1981 2
1982 4
1983 1
1984 2
1985 4
1986 3
1987 2
1988 1
1989 4
1990 1
1991 5
1992 3
1993 2
1994 5
1995 7
1996 4
1997 8
1998 5
1999 5
2000 9
2001 14
2002 4
2003 9
2004 6
2005 4
2006 6
2007 4
2008 3
2009 7
2010 4
2011 11
2012 12
2013 8
2014 5
2015 8
2016 8
2017 11
2018 19
2019 21
2020 29
2021 24
2022 26
2023 25
2024 23
2025 35
2026 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

396 results

Results by year

Filters applied: . Clear all
Page 1
Improved Event-Free Survival After Complete or Major Pathologic Response in Patients With Resectable NSCLC Treated With Neoadjuvant Chemoimmunotherapy Regardless of Adjuvant Treatment: A Systematic Review and Individual Patient Data Meta-Analysis.
Marinelli D, Nuccio A, Di Federico A, Ambrosi F, Bertoglio P, Faccioli E, Ferrara R, Ferro A, Giusti R, Guerrera F, Mammana M, Pittaro A, Sepulcri M, Viscardi G, Gallina FT. Marinelli D, et al. Among authors: ferrara r. J Thorac Oncol. 2025 Mar;20(3):285-295. doi: 10.1016/j.jtho.2024.09.1443. Epub 2024 Oct 9. J Thorac Oncol. 2025. PMID: 39389220 Free article.
Treatment of NSCLC after chemoimmunotherapy - are we making headway?
Reck M, Frost N, Peters S, Fox BA, Ferrara R, Savai R, Barlesi F. Reck M, et al. Among authors: ferrara r. Nat Rev Clin Oncol. 2025 Nov;22(11):806-830. doi: 10.1038/s41571-025-01061-7. Epub 2025 Aug 14. Nat Rev Clin Oncol. 2025. PMID: 40813911 Review.
Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.
Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D, Ponce S, Ares LP, Leroy L, Audigier-Valette C, Felip E, Zerón-Medina J, Garrido P, Brosseau S, Zalcman G, Mazieres J, Caramela C, Lahmar J, Adam J, Chaput N, Soria JC, Besse B. Mezquita L, et al. Among authors: ferrara r. JAMA Oncol. 2018 Mar 1;4(3):351-357. doi: 10.1001/jamaoncol.2017.4771. JAMA Oncol. 2018. PMID: 29327044 Free PMC article.
Neoadjuvant vs perioperative chemo-immunotherapy according to pathological response in resectable non-small cell lung cancer: a reconstructed individual patient data meta-analysis.
Nuccio A, Salomone F, Servetto A, Ricciuti B, Marinelli D, Bulotta A, Veronesi G, Garassino MC, Torri V, Besse B, Viscardi G, Ferrara R. Nuccio A, et al. Among authors: ferrara r. J Natl Cancer Inst. 2025 Nov 1;117(11):2388-2393. doi: 10.1093/jnci/djaf090. J Natl Cancer Inst. 2025. PMID: 40210599
Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer.
Arbour KC, Mezquita L, Long N, Rizvi H, Auclin E, Ni A, Martínez-Bernal G, Ferrara R, Lai WV, Hendriks LEL, Sabari JK, Caramella C, Plodkowski AJ, Halpenny D, Chaft JE, Planchard D, Riely GJ, Besse B, Hellmann MD. Arbour KC, et al. Among authors: ferrara r. J Clin Oncol. 2018 Oct 1;36(28):2872-2878. doi: 10.1200/JCO.2018.79.0006. Epub 2018 Aug 20. J Clin Oncol. 2018. PMID: 30125216 Free article.
DNA methyltransferase 3A (DNMT3A) mutations and PD-(L)1 blockade efficacy in non-small-cell lung cancer.
Ricciuti B, Scalera S, Wang X, Elkrief A, Tagliamento M, Gariazzo E, Paoloni F, Miller PG, Pecci F, Di Federico A, Santo V, Alessi JV, Aldea M, Garbo E, Lamberti G, Zrafi W, Micol JB, Sholl LM, Nishino M, Cappuzzo F, Calonaci N, Caravagna G, Ferrara R, Besse B, Schoenfeld A, Maugeri-Sacca M, Awad MM. Ricciuti B, et al. Among authors: ferrara r. Ann Oncol. 2025 Oct;36(10):1132-1141. doi: 10.1016/j.annonc.2025.06.003. Epub 2025 Jun 18. Ann Oncol. 2025. PMID: 40541864 Free PMC article.
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAFV600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study.
Di Federico A, Wang K, Chen MF, Barsouk AA, Pagliaro A, Chen LN, Ogliari FR, Stockhammer P, Thawani R, Raslan S, Gariazzo E, Fusco F, Hambelton GM, Citarella F, Meyer D, Aldea M, De Giglio A, Alessi JV, Pecci F, Gelsomino F, Corassa M, Vokes NI, Wang X, de Biase D, Abu Rous F, Areesawangkit P, Elghawy O, Cortellini A, Metro G, Ferrara R, Awad MM, Pabani A, Murray JC, Cappuzzo F, Garassino MC, Dagogo-Jack I, Riely G, Grant M, Herzberg BO, Ardizzoni A, Planchard D, Johnson BE, Langer CJ, Offin M, Negrao MV, Ricciuti B. Di Federico A, et al. Among authors: ferrara r. Lancet Oncol. 2025 Oct;26(10):1357-1369. doi: 10.1016/S1470-2045(25)00409-7. Lancet Oncol. 2025. PMID: 41038185
Eating away T cell responses in lung cancer.
Ferrara R, Roz L. Ferrara R, et al. J Exp Med. 2022 Dec 5;219(12):e20221449. doi: 10.1084/jem.20221449. Epub 2022 Oct 10. J Exp Med. 2022. PMID: 36214813 Free PMC article.
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry.
Cortellini A, Brunetti L, Di Fazio GR, Garbo E, Pinato DJ, Naidoo J, Katz A, Loza M, Neal JW, Genova C, Gettinger S, Kim SY, Jayakrishnan R, El Zarif T, Russano M, Pecci F, Di Federico A, Awad M, Alessi JV, Montrone M, Owen DH, Signorelli D, Fidler MJ, Li M, Camerini A, De Giglio A, Young L, Vincenzi B, Metro G, Passiglia F, Yendamuri S, Guida A, Ghidini M, Awosika NO, Napolitano A, Fulgenzi CAM, Grisanti S, Grossi F, D'Incecco A, Josephides E, Van Hemelrijck M, Russo A, Gelibter A, Spinelli G, Verrico M, Tomasik B, Giusti R, Newsom-Davis T, Bria E, Sebastian M, Rost M, Forster M, Mukherjee U, Landi L, Mazzoni F, Aujayeb A, Dupont M, Curioni-Fontecedro A, Chiari R, Pantano F, Morabito A, Leonetti A, Friedlaender A, Addeo A, Zoratto F, De Tursi M, Cantini L, Roca E, Mountzios G, Della Gravara L, Kalvapudi S, Inno A, Bironzo P, Di Marco Barros R, O'Reilly D, Bell J, Karapanagiotou E, Monnet I, Baena J, Macerelli M, Majem M, Agustoni F, Cortinovis DL, Tonini G, Minuti G, Bennati C, Mezquita L, Gorría T, Servetto A, Beninato T, Lo Russo G, Rogado J, Moliner L, Biello F, Aboubakar Nana F, Dingemans AM, Aerts JGJV, Ferrara R, Torri V, Hejleh TA, Takada K, Naqash AR, Garassino M, … See abstract for full author list ➔ Cortellini A, et al. Among authors: ferrara r. J Immunother Cancer. 2025 Feb 4;13(2):e010674. doi: 10.1136/jitc-2024-010674. J Immunother Cancer. 2025. PMID: 39904562 Free PMC article.
Unleashing precision: A review of targeted approaches in pleural mesothelioma.
Occhipinti M, Brambilla M, Di Liello R, Ambrosini P, Lobianco L, Leporati R, Salvarezza M, Vitiello F, Marchesi S, Manglaviti S, Beninato T, Mazzeo L, Proto C, Prelaj A, Ferrara R, Della Corte CM, Lo Russo G, de Braud F, Ganzinelli M, Viscardi G. Occhipinti M, et al. Among authors: ferrara r. Crit Rev Oncol Hematol. 2024 Nov;203:104481. doi: 10.1016/j.critrevonc.2024.104481. Epub 2024 Aug 17. Crit Rev Oncol Hematol. 2024. PMID: 39159705 Free article. Review.
396 results